



---

## NOXIVENT<sup>®</sup> Indication and Important Safety Information

---

**Indication** Noxivent is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

---

### Important Safety Information

#### **Contraindications**

Noxivent is contraindicated in neonates dependent on right-to-left shunting of blood.

#### **Warnings and Precautions**

**Rebound:** Abrupt discontinuation of Noxivent may lead to worsening oxygenation and increasing pulmonary artery pressure.

**Methemoglobinemia:** Methemoglobin levels increase with the dose of Noxivent; it can take 8 hours or more before steady-state methemoglobin levels are attained. If methemoglobin levels do not resolve with decrease in dose or discontinuation of Noxivent, additional therapy may be warranted to treat methemoglobinemia.

**Airway injury from Nitrogen Dioxide:** Monitor nitrogen dioxide (NO<sub>2</sub>) levels. Nitrogen dioxide may cause airway inflammation and damage to lung tissue.

**Heart Failure:** In patients with pre-existing left ventricular dysfunction, Noxivent may increase pulmonary capillary wedge pressure leading to pulmonary edema.

**Adverse Reactions:** The most common adverse reaction of Noxivent is hypotension.

**Drug Interactions:** Nitric Oxide donor compounds may increase the risk of developing methemoglobinemia.

#### **Administration**

Use only with a calibrated NOxBOXi<sup>®</sup> delivery system operated by trained personnel. Only validated ventilator systems should be used in conjunction with Noxivent.

[Please see the full Prescribing Information for additional important Noxivent safety and risk information.](#)